Value of aMAP score in prediction of hepatocellular carcinoma risk in outpatients with chronic hepatitis B virus infection
10.3969/j.issn.1001-5256.2022.10.009
- VernacularTitle:aMAP评分评估门诊慢性HBV感染者肝细胞癌风险的价值分析
- Author:
Limin WANG
1
;
Hongfei ZHANG
1
;
Yu GAN
1
;
Si XIE
2
;
Jingyue WANG
2
;
Yuan HUANG
2
Author Information
1. Department of Children's Liver Diseases, Beijing Tsinghua Changgung Hospital, Beijing 102218, China
2. Department of Hepatobiliary and Pancreatic Medicine, Beijing Tsinghua Changgung Hospital, Beijing 102218, China
- Publication Type:Original Article_Viral Hepatitis
- Keywords:
Carcinoma, Hepatocellular;
Hepatitis B Virus;
aMAP Score
- From:
Journal of Clinical Hepatology
2022;38(10):2242-2246
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the aMAP risk in prediction of hepatocellular carcinoma (HCC) risk in outpatients with chronic hepatitis B virus (HBV) infection. Methods A total of 709 patients with chronic HBV infection were recruited for calculation of the aMAP scores and then stratified for HCC risk statistically. The t -test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups. Results Among these 709 patients, 22.4% had complicated with alcoholic liver disease, 11.8% with diabetes mellitus. 18.6% with fatty liver, 19.0% with liver cirrhosis, and 9.7% with liver cancer. Among all patients, 71.2% received oral antiviral medicine. Moreover, the highest aMAP score was 75.2 and the low, medium and high HCC risks were 70.0%, 23.1%, and 6.9% respectively in these patients. The proportion of patients with high HCC risk was higher among those with alcohol liver disease, diabetes mellitus, and liver cirrhosis than those without these complications (9.4% vs 6.2%; 11.9% vs 6.2%; and 19.3% vs 4.0%). The mean annual change in aMAP score was 0.93±2.05 in patients without antiviral treatment that was higher than -1.15±1.72 in patients with antiviral treatment ( t =39.36; P < 0.001). In addition, the proportion of these patients with high HCC risk three years before HCC diagnosis was 38.4%, 26.7%, and 33.3% respectively. The median of aMAP score was more than 50 three years before diagnosis liver cancer, data of which indicated that this change was earlier than that of AFP. Conclusion aMAP is a simple convenient marker for screening early HCC in outpatient with chronic HBV infection and complications, especially in those patients with alcohol liver disease, diabetes, and cirrhosis. Oral antiviral therapy could reduce aMAP in patients with chronic HBV infection.
